MET and non-small cell lung carcinoma: Here, we summarize the correlation between biomarker validation or clinical inclusion criteria and the therapeutic efficacy of selective MET/HGF kinase inhibitors or antibodies in clinical trials of multiple solid tumors, including GC, NSCLC and HCC.